BR112022026386A2 - Inibidor de fgfr e mutação, método de preparação do mesmo e uso farmacêutico do mesmo - Google Patents

Inibidor de fgfr e mutação, método de preparação do mesmo e uso farmacêutico do mesmo

Info

Publication number
BR112022026386A2
BR112022026386A2 BR112022026386A BR112022026386A BR112022026386A2 BR 112022026386 A2 BR112022026386 A2 BR 112022026386A2 BR 112022026386 A BR112022026386 A BR 112022026386A BR 112022026386 A BR112022026386 A BR 112022026386A BR 112022026386 A2 BR112022026386 A2 BR 112022026386A2
Authority
BR
Brazil
Prior art keywords
fgfr
preparation
mutation
same
inhibitor
Prior art date
Application number
BR112022026386A
Other languages
English (en)
Inventor
Deng Haibing
Ying Haiyan
Yu Hongping
Chen Zhui
Xu Yaochang
Original Assignee
Abbisko Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbisko Therapeutics Co Ltd filed Critical Abbisko Therapeutics Co Ltd
Publication of BR112022026386A2 publication Critical patent/BR112022026386A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

INIBIDOR DE FGFR E MUTAÇÃO, MÉTODO DE PREPARAÇÃO DO MESMO E USO FARMACÊUTICO DO MESMO. São fornecidos um inibidor de FGFR e mutação, e um método de preparação do mesmo e o uso do mesmo. Em particular, são fornecidos um inibidor de FGFR e mutação que tem uma estrutura de fórmula (I), um método de preparação do mesmo, uma composição farmacêutica contendo o mesmo, o uso do mesmo como um inibidor de FGFR e mutação e o uso do mesmo na preparação de um fármaco para tratar e/ou prevenir tumores ou cânceres mediados pelo menos em parte por meio de uma FGFR quinase e para o tratamento de um paciente com tumor que tem resistência a um inibidor de FGFR, e, em particular, o uso do mesmo na preparação de um fármaco para tratar e/ou prevenir um paciente com tumor com mutações em V561, V565, N550, N540, V555, E566, K660 e/ou V550 de uma via de sinalização de FGFR. Cada substituinte de fórmula (I) tem a mesma definição que na descrição.
BR112022026386A 2020-08-13 2021-08-11 Inibidor de fgfr e mutação, método de preparação do mesmo e uso farmacêutico do mesmo BR112022026386A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010811490 2020-08-13
PCT/CN2021/112121 WO2022033532A1 (zh) 2020-08-13 2021-08-11 一种fgfr及其突变抑制剂，其制备方法和应用

Publications (1)

Publication Number Publication Date
BR112022026386A2 true BR112022026386A2 (pt) 2023-02-23

Family

ID=80246991

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026386A BR112022026386A2 (pt) 2020-08-13 2021-08-11 Inibidor de fgfr e mutação, método de preparação do mesmo e uso farmacêutico do mesmo

Country Status (11)

Country Link
US (1) US20230303575A1 (pt)
EP (1) EP4169922A4 (pt)
JP (1) JP2023530768A (pt)
KR (1) KR20230015419A (pt)
CN (1) CN115485281B (pt)
AU (1) AU2021323844B2 (pt)
BR (1) BR112022026386A2 (pt)
CA (1) CA3184247A1 (pt)
MX (1) MX2023000008A (pt)
TW (1) TWI797711B (pt)
WO (1) WO2022033532A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230374015A1 (en) * 2020-06-05 2023-11-23 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
CN115785103A (zh) * 2022-12-28 2023-03-14 北京康立生医药技术开发有限公司 一种治疗胆管癌药物福巴替尼的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200738725A (en) * 2006-01-25 2007-10-16 Osi Pharm Inc Unsaturated mTOR inhibitors
DK2657233T3 (da) * 2012-01-19 2014-09-22 Taiho Pharmaceutical Co Ltd 3,5-disubstitueret alkynylbenzenforbindelse og salt deraf
PT3023100T (pt) * 2013-07-18 2019-05-29 Taiho Pharmaceutical Co Ltd Fármaco antitumoral para administração intermitente de inibidor de fgfr
WO2015008844A1 (ja) * 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
CN105461720B (zh) * 2014-08-08 2019-08-06 南京圣和药业股份有限公司 吗啉类酪氨酸激酶抑制剂
CN107344940B (zh) * 2016-05-06 2020-04-21 广东东阳光药业有限公司 Btk抑制剂及其用途
CN109776544B (zh) * 2017-11-15 2022-02-01 上海医药工业研究院 吡唑并[3,4-d]嘧啶类化合物及其制备方法和用途
US20230374015A1 (en) * 2020-06-05 2023-11-23 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases

Also Published As

Publication number Publication date
CA3184247A1 (en) 2022-02-17
JP2023530768A (ja) 2023-07-19
KR20230015419A (ko) 2023-01-31
AU2021323844A1 (en) 2023-01-19
EP4169922A1 (en) 2023-04-26
MX2023000008A (es) 2023-01-30
WO2022033532A1 (zh) 2022-02-17
AU2021323844B2 (en) 2023-07-27
CN115485281A (zh) 2022-12-16
US20230303575A1 (en) 2023-09-28
TW202206433A (zh) 2022-02-16
CN115485281B (zh) 2023-11-21
EP4169922A4 (en) 2024-03-13
TWI797711B (zh) 2023-04-01

Similar Documents

Publication Publication Date Title
MX2021005011A (es) Métodos de tratamiento del cáncer en pacientes identificados por biomarcadores con inhibidores no covalentes de cinasa 7 dependiente de ciclina (cdk7).
Synnott et al. Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer?
Yi et al. Inhibition of the PI 3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple‐negative breast cancer cells
Gorecki et al. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy
BR112021023136A2 (pt) Compostos heterocíclicos, métodos de preparação e usos dos mesmos
Dutta et al. Cellular responses to EGFR inhibitors and their relevance to cancer therapy
BR112022026386A2 (pt) Inibidor de fgfr e mutação, método de preparação do mesmo e uso farmacêutico do mesmo
BRPI0511760A (pt) tratamento com gemcitabina e um inibidor de egfr
BRPI0510657A (pt) tratamento com cisplatina e com um inibidor de egfr
BR112022002532A2 (pt) Compostos heterocíclicos como inibidores de quinase
Yi et al. Inhibition of constitutively activated phosphoinositide 3‐kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1‐defective breast cancer cells
BRPI0517075A (pt) uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer
BR112016028641A2 (pt) ?método para tratar câncer?
BR112014016163A8 (pt) piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp
Preuß et al. Pasteurella multocida toxin is a potent activator of anti‐apoptotic signalling pathways
Li et al. Quercetin‐3‐methyl ether inhibits lapatinib‐sensitive and‐resistant breast cancer cell growth by inducing G2/M arrest and apoptosis
HK1145832A1 (en) Pyrimidine substituted purine derivatives
BR0308030A (pt) Derivados de 5-feniltiazol e uso como inibidores de pi3 cinase
BR112012010124A2 (pt) composto, uso de um animal composto, derivado de cromenona, e, método para o tratamento ou prevenção de um animal de sangue quente tendo tumores que são sensíveis á inibição das enzimas de pi 3-cinase
BR112017005531A2 (pt) derivados de diaril ureia como inibidores de quinase p38
BR112022011998A2 (pt) Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas
Caldwell et al. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia
Wayne et al. Targeting DNA damage response pathways to activate the STING innate immune signaling pathway in human cancer cells
BR112022000251A2 (pt) Derivados macrocíclicos de espirociclo como inibidores de mcl-1
Hastak et al. Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers